Oral and Poster Abstracts
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
CML, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Yingling Zu1*, Huifang Zhao2*, Jianling Chen3*, Huibing Dang4*, Yanrong Shi5*, Lixin Liang6*, Shuhao Mei7*, Wenyi Lu8, Jian Zhou, MD, PhD9*, Yongping Song10* and Yanli Zhang, MD2*
1Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, zhengzhou, China
2Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
3Department of Hematology, Pingdingshan the Second People’s Hospital, pingdingshan, China
4Department of Hematology, The First Affiliated Hospital of Nanyang Medical College, nanyang, China
5Department of Hematology, General Hospital of Pingmei Shenma Medical Group, pingdingshan, China
6Department of Hematology, Sanmenxia Central Hospital, sanmenxia, China
7Department of Hematology, Xuchang Central Hospital, xuchang, China
8Department of Hematology, Henan Provincial People's Hospital, zhengzhou, China
9Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
10Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Introduction In the era of tyrosine kinase inhibitor (TKI), improving the quality of life has become the main therapeutic goal for patients with chronic myeloid leukemia (CML). Unintended pregnancy for female patients with chronic myeloid leukemia (CML) raises the discussion of treatment choices due to the teratogenicity of tyrosine kinase inhibitor (TKI).
Method We reported 51 accidental pregnant CML chronic phase (CP) patients with TKI withdrawal immediately after pregnancy from December 2010 to February 2024 to observe the effect of short exposure to TKI on the fetus and the infant outcomes.
Results 59 pregnancies resulted in 100% normal childbirth without birth abnormalities. The median TKI exposure duration was 4 (4-20) weeks in 58 pregnancies, and one pregnancy avoided TKI exposure due to treatment discontinuation of the patient with treatment-free remission (TFR). All newborns had normal birth weight except one premature infant with low birth weight less than the 10th percentile. Up to now, all the children are in good health. 13 (25.5%) and 30 (58.8%) patients had achieved major molecular response (MMR) and deep molecular response (DMR) at pregnancy, respectively. After TKI discontinuation, loss of MMR and complete hematologic response occurred in 6 (11.8%) and 2 (3.9%) patients at delivery, respectively. 38 patients resumed TKI treatment after delivery, and 13 patients sustained TFR after delivery. The median time to regain MMR and DMR were 3 (2-6) months and 6 (1-28) months, respectively.
Conclusion These results demonstrate that TKI discontinuation during pregnancy is feasible for CML-CP patients, and short TKI exposure of pregnant patients has little influence on children's growth and development.
Disclosures: No relevant conflicts of interest to declare.
*signifies non-member of ASH